Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar;7(1):8-14.
doi: 10.2174/157340711795163866.

CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development

Cissy Young  1 , Thomas Schluep, Jungyeon Hwang, Scott Eliasof
Affiliations
Free PMC article

CRLX101 (formerly IT-101)-A Novel Nanopharmaceutical of Camptothecin in Clinical Development

Cissy Young et al. Curr Bioact Compd. 2011 Mar.
Free PMC article

Abstract

CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin polymeric nanoparticle technology, referred to as "CDP", has unique design features and capabilities. Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Schematic diagram of CRLX101, a nanopharmceutical comprised of camptothecin conjugated to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer and formulated into nanoparticles.
Fig. (2)
Fig. (2)
Cryo-TEM of CRLX101.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee K-D, Woodle MC, Lasic DD, Redemann C, Martin FJ. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic effect. Proc. Natl. Acad. Sci. USA. 1991;88:11460–11464. - PMC - PubMed
    1. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008;7:771–782. - PubMed
    1. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392. - PubMed
    1. Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 1992;52:6774–6781. - PubMed
    1. Tong R, Cheng J. Anticancer polymeric nanomedicines. Polymer Rev. 2007;47:345–381.